Form 8-K - Current report:
SEC Accession No. 0000950123-24-003417
Filing Date
2024-04-22
Accepted
2024-04-22 08:11:29
Documents
11
Period of Report
2024-04-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 FORM 8-K lxeo-20240422.htm   iXBRL 8-K 37310
  Complete submission text file 0000950123-24-003417.txt   153929

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lxeo-20240422.xsd EX-101.SCH 25988
14 EXTRACTED XBRL INSTANCE DOCUMENT lxeo-20240422_htm.xml XML 4931
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41855 | Film No.: 24859555
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)